Abstract
Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression.
Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.Keywords: Autoantibodies, type 1 diabetes, prediction, prevention, biomarker, diabetogenesis.
Current Diabetes Reviews
Title:Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Volume: 13 Issue: 3
Author(s): Georgia Fousteri*, Elio Ippolito, Rizwan Ahmed and Abdel Rahim A. Hamad
Affiliation:
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan,Italy
Keywords: Autoantibodies, type 1 diabetes, prediction, prevention, biomarker, diabetogenesis.
Abstract: Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression.
Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.Export Options
About this article
Cite this article as:
Fousteri Georgia*, Ippolito Elio, Ahmed Rizwan and A. Hamad Rahim Abdel, Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666160427104157
DOI https://dx.doi.org/10.2174/1573399812666160427104157 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with an increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to microcirculatory disturbances and reduced levels of endogenous growth factors. Delayed cutaneous wound healing is a chronic ...read more
Advancing Insights into Type 1 Diabetes: From Mechanisms to Management
Type 1 diabetes (T1D) represents a significant global health challenge, requiring a deep understanding of its complex pathophysiology and the development of innovative strategies for prevention, treatment, and management. This thematic issue highlights the latest progress in understanding the autoimmune processes underlying T1D, advances in beta-cell biology, and novel therapeutic ...read more
Exerscience: Management of Diabetes by Physical Activity/Exercise
Physical activity/exercise is key to the management of diabetes and its complications. Studies have suggested that increased physical activity or regular exercise is associated with reduced risks of diabetes and its complications. However, challenges remained on how to promote physical activity or exercise efficiently, e.g., increase the adherence to physical ...read more
Next-Generation Drug Delivery Systems for Diabetes: Nanoparticles, Hydrogels, and Phytosome Technologies
This thematic issue, titled "Next-Generation Drug Delivery Systems for Diabetes: Nanoparticles, Hydrogels, and Phytosome Technologies," will focus on advanced formulation science to enhance diabetes treatment. It covers innovative platforms such as nanoparticles, responsive hydrogels, and phytosome technologies for improving the bioavailability, stability, and precision in delivering antidiabetic agents. Key areas ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clozapine Safety, 35 Years Later
Current Drug Safety Growing Burden of Diabetes in Sub- Saharan Africa: Contribution of Pesticides ?
Current Diabetes Reviews Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Identifying Knowledge Deficits of Food Insecure Patients with Diabetes
Current Diabetes Reviews Clozapine Safety, 40 Years Later
Current Drug Safety Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Type 1 Diabetes in Young Adulthood
Current Diabetes Reviews Advanced Approaches in Insulin Delivery
Current Pharmaceutical Biotechnology Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology Model-Based Insulin and Nutrition Administration for Tight Glycaemic Control in Critical Care
Current Drug Delivery NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic:Continuous Glucose Monitoring Systems: Toys or Tools (Guest Editor: Christophe De Block)]
Current Diabetes Reviews Extracellular Hsp70: Export and Function
Current Protein & Peptide Science Role of NFAT5 in Inflammatory Disorders Associated with Osmotic Stress
Current Genomics Peptide Immunotherapies in Type 1 Diabetes: Lessons from Animal Models
Current Medicinal Chemistry Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology